Fortitude Family Office’s MBX Biosciences MBX Stock Holding History

Fortitude Family Office’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.28K	Buy	56 +37	+195%	+$2.32K	﹤0.01%	1785
2026 Q2	$1.05K	Hold	19	–	–	﹤0.01%	1743
2026 Q1	$567	Buy	+19	New	+$646	﹤0.01%	1677

Other funds holding MBX

AWA

Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

KWM

Koa Wealth Management Encinitas, California $154M AUM 13.16% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fortitude Family Office's MBX Position: Q3 2026 in Review

Fortitude Family Office increased its MBX Biosciences (MBX) stake by 195% in Q3 2026, buying an estimated $2.32K and bringing the position to 56 shares worth $3.28K. The position accounts for ﹤0.01% of the portfolio, ranked #1785.

Fortitude Family Office first reported a position in MBX in Q1 2026 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold MBX as of Q3 2026.

Fortitude Family Office held 56 shares of MBX Biosciences worth $3.28K as of Q3 2026.
Fortitude Family Office bought 37 MBX Biosciences shares in Q3 2026, an estimated $2.32K.
MBX Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1785 holding.
Fortitude Family Office first reported a position in MBX Biosciences in Q1 2026 and has held it in 3 quarters since.
8 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.